埃斯頓(002747.SZ):公司已在人形機器人方面有佈局
格隆匯5月14日丨埃斯頓(002747.SZ)在2023年度網上業績説明會表示,公司已在人形機器人方面有佈局。公司底層技術與人形機器人的開發有相通性,公司參股了南京埃斯頓酷卓科技有限公司(以下簡稱"酷卓"),其業務包含了人形機器人的部件及算法的研發,未來基於多場景交錯互補模式,酷卓的產品研發可以進一步豐富公司的產品組合及技術佈局,有利於加深公司與酷卓在高柔性智能化機器人及具身智能等相關領域的業務合作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.